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Abstract
In West Africa, Trypanosoma brucei gambiense, causing human African trypanosomiasis (HAT), is associated with a great
diversity of infection outcomes. In addition to patients who can be diagnosed in the early hemolymphatic phase (stage 1) or
meningoencephalitic phase (stage 2), a number of individuals can mount long-lasting specific serological responses while
the results of microscopic investigations are negative (SERO TL+). Evidence is now increasing to indicate that these are
asymptomatic subjects with low-grade parasitemia. The goal of our study was to investigate the type of immune response
occurring in these ‘‘trypanotolerant’’ subjects. Cytokines levels were measured in healthy endemic controls (n = 40), stage 1
(n = 10), early stage 2 (n = 19), and late stage 2 patients (n = 23) and in a cohort of SERO TL+ individuals (n = 60) who were
followed up for two years to assess the evolution of their parasitological and serological status. In contrast to HAT patients
which T-cell responses appeared to be activated with increased levels of IL2, IL4, and IL10, SERO TL+ exhibited high levels of
proinflammatory cytokines (IL6, IL8 and TNFa) and an almost absence of IL12p70. In SERO TL+, high levels of IL10 and low
levels of TNFa were associated with an increased risk of developing HAT whereas high levels of IL8 predicted that serology
would become negative. Further studies using high throughput technologies, hopefully will provide a more detailed view of
the critical molecules or pathways underlying the trypanotolerant phenotype.
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Introduction
Human African trypanosomiasis (HAT), or sleeping sickness,
caused by Trypanosoma brucei gambiense (T. b. gambiense) is
classically described as a chronic infection characterized by an
early hemolymphatic stage (stage 1) associated with nonspecific
symptoms such as intermittent fevers and headaches, followed by a
meningoencephalitic stage (stage 2) in which the parasite invades
the central nervous system and causes neurological disorders and
death if left untreated. Long considered as invariably fatal,
observations are increasingly indicating that infection by T. b.
gambiense can result in a wide range of clinical outcomes in its
human host [1–3]. Recently, self-cure processes have been
described in HAT patients refusing treatment in Coˆte d’Ivoire
[4]. Furthermore, individuals with (i) high responses to the card
agglutination test for trypanosomiasis (CATT); (ii) serological
positivity to the highly specific T. b. gambiense immune
trypanolysis test (TL) and (iii) negative parasitological results
(SERO TL+) have been reported from a number of endemic foci
in West Africa [5,6]. Noteworthy, follow-up studies showed that
only some of these subjects develop HAT (parasite can be detected
by microscopy in body fluids) while others are able to maintain
high and specific serological responses over long periods of time
[7]. These observations suggest that SERO TL+ individuals have
been in contact with T.b. gambiense and that some of them are
able to control infection to levels that cannot be detected by
microscopy. This hypothesis is supported by the fact that parasite
DNA can be detected by PCR in this category of subjects [7,8]
and that direct microsatellite typing of trypanosomes from blood
samples detected the same genotypes as those found in HAT
patients [9]. Overall, these field observations are in line with the
idea that trypanotolerance exists in humans, too, as demonstrated
in some West African taurine breeds and in inbred mice models
displaying differential susceptibility toinfection [10,11].
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While several studies were designed to investigate the immune
response in HAT patients at different stages of disease [12,13],
almost nothing is known about the response occurring in SERO
TL+ subjects who are apparently able to control infection. In this
study, we evaluated the levels of 10 cytokines (IL12p70, IL2, IL4,
IL5, IL8, IL1b, IL6, IL10, tumor necrosis factor (TNF)a, and
interferon (INF)c) in HAT patients, SERO TL+ subjects and
endemic controls recruited during medical surveys which were
conducted in active HAT foci in Guinea. In addition, SERO TL+
subjects were followed up for at least 2 years in order to analyze
the prognostic value of cytokine levels determined at study
inclusion on the subsequent evolution of the serological and
parasitological status: (i) development of HAT; (ii) maintenance of
high antibody responses, and (iii) progressive decrease in antibody
responses.
Materials and Methods
Study population and definition of phenotypes
The study was carried out in three active HAT foci (Dubreka,
Boffa, and Forecariah) located in mangrove areas of coastal
Guinea [14]. Most of the population is from the Soussou ethnic
group and lives in small villages scattered along mangrove
channels. Main occupations are rice cultivation, fishing, wood
cutting, and salt extracting, all activities that bring the population
into close contact with Glossina palpalis gambiensis which is the
only vector of T. b. gambiense in these areas [15,16]. Other
diseases such as tuberculosis, leprosy or cholera are still present
and malaria is highly endemic.
All subjects included in this study were identified during medical
surveys organized by the National Control Programme (NCP)
between November 2007 and May 2011, according to the WHO
and NCP policies, as described previously [7]. During the surveys
a total of 41,311 individuals were screened, blood (5 ml) was
collected in heparanized tubes from all individuals who tested
positive to the CATT mass screening test, and a twofold plasma
dilution series was tested to determine the CATT end titer. All
individuals with end titers of 1/8 or greater were submitted to
microscopic examination of lymph node aspirates whenever
swollen lymph nodes were present; 350 ml of buffy coat was then
examined by using the mini-anion exchange centrifugation test
which has shown to have a positive threshold of 10 trypanosomes/
ml of blood [15]. When trypanosomes were detected, lumbar
puncture was performed and the disease stage determined by
searching for trypanosomes using the modified simple centrifuga-
tion technique [17] of cerebrospinal fluid (CSF) and by white
blood cell (WBC) counts. HAT patients were classified as stage 1
(0–5 WBC/ml), early stage 2 (6–20 WBC/ml; or #20 WBC with
trypanosomes in CSF), or late stage 2 (.20 WBC/ml) and treated
according to the NCP recommendations. In addition to HAT
patients (n = 108) and CATT plasma-positive subjects (SERO,
n=84), 5 ml of blood was also taken from CATT-negative
individuals (n = 42) selected from the same CATT series as the
HAT and SERO subjects and subjected to the same tests as
described above. For all subjects, aliquots were made with leftover
plasma and with CSF for HAT patients when available. Collected
samples were then frozen directly in the field in a liquid nitrogen
container and stored at 280uC at CIRDES until use. For each
individual, an aliquot of plasma was used to perform the immune
trypanolysis test that detects Litat 1.3 and Litat 1.5 variable surface
antigens specific for T. b. gambiense [6]. The 24 SERO that were
negative and the two endemic controls that were positive were
excluded at this stage of the study; all HAT patients who were
positive and those for whom both plasma and CSF samples were
available (n = 52) were included in the study: 10, 19, and 23 were
classified as stage 1, early stage 2, and late stage 2, respectively.
The study sample phenotypic and demographic characteristics are
summarized in Table 1. All SERO TL+ individuals were then
followed up at their home for 2 years. When present, serological
and parasitological tests were repeated as described above. Out of
the 60 SERO TL+, 40 could be followed up for at least 2 years (on
average 3 visits) and were included in the analysis of the prognostic
value of cytokine levels in the evolution of the serological and
parasitological status.
Cytokines assays
Plasma cytokine levels (IL12p70, IL2, IL4, IL5, TNFa, INFc,
IL8, IL1b, IL6, and IL10) were determined for all study subjects
with the human Th1/Th2 and human inflammation Cytometry
Bead Array (CBA) cytokine kits according to the manufacturer’s
instructions (BD, Biosciences). For CSF samples we used only the
human inflammation CBA kit to quantify IL8, IL1b, IL6, IL10,
IL12, and TNFa levels. After acquiring sample data by flow
cytometry (BD FACSCanto) and the BD FACSDiva software,
results were generated in a graphical and tabular format using the
Flow Cytometric Analysis Program Array software (FCAP Array,
BD Biosciences).
Statistical analysis
Univariate analysis of cytokine levels between groups was
performed by using the nonparametric Wilcoxon signed-rank test
(Kruskal-Wallis). The association between cytokine levels and the
risk to develop HAT in SERO TL+ individuals was also evaluated
by stepwise multivariate logistic regression. The covariates
included in these analyses were age (in years), gender, and
cytokine levels. Cytokine levels were assigned to two classes of
equal size using the median cytokine value as the threshold. The
most significant covariates (P,0.1) were then entered one by one
until no significant improvement in the model likelihood ratio was
observed. The JMP5 (SAS Institute) software was used for
univariate analyses and multivariate logistic regressions and the
R software was used for the construction of box-plots. Normed
principal component analysis (PCA) was performed using the ade4
package in the R environment [18] with cytokines data ln(1+x)
transformed. The association between each of the study recorded
covariates and the individuals x and y coordinates on the first
factorial plan was assessed by logistic regression for qualitative
Author Summary
Whereas immunological mechanisms involved in the
control of trypanosome infections have been extensively
studied in animal models, knowledge of how Trypanosoma
brucei gambiense interacts with its human hosts lags far
behind. In this study we measured cytokine levels in
sleeping sickness patients and individuals who were
apparently able to control infection to subdetection levels
over long periods of time or who were engaged in a
process of self-cure as demonstrated by the disappearance
of specific antibodies. In contrast to patients, trypanoto-
lerant subjects were characterized by a strong inflamma-
tory response with elevated levels of IL8, IL6, and TNFa.
This study indicates that both protective immune respons-
es and markers of disease development exist in human T.
brucei. gambiense infection and constitute an important
step forward to identify new diagnostic or therapeutic
targets in the fight against sleeping sickness.
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covariates (HAT status, disease stage in HAT patients, gender and
disease geographic focus) and by linear regression for age.
Ethical considerations
This study was performed as part of medical surveys conducted
by the NCP according to the national HAT diagnostic procedures
and was approved by the Ministry of Health in Guinea. All
participants were informed of the objectives of the study in their
own language and signed a written informed consent form. For
participants under 18 years of age, a written informed consent was
obtained from the parents. This study is part of a larger project
aiming to improve HAT diagnosis for which approval was
obtained from the World Health Organization (WHO, Research
Ethics Review Committee) and IRD (Comite´ Consultatif de
De´ontologie et d’Ethique) ethical committees.
Results
Cytokine levels in CSF and plasma according to disease
stage
Mean cytokines levels measured in the CSF and plasma samples
of HAT patients in the different disease stages are shown in
Table 2. In the CSF, TNFa, IL1b and IL12 levels were similar in
all stages. Patients in the second stage of disease had significantly
higher IL10 (p = 0.0003), IL8 (p = 0.001), and IL6 (p = 0.01) levels
in CSF than patients in stage 1 or early stage 2. In contrast, none
of the cytokines measured in the plasma displayed a significant
association according to the disease stage although a trend was
observed for IL1b and INFc levels to be increased along with
disease severity (Figure S1). On the basis of these results, we
gathered all patients into one single group (HAT patients group) in
order to further compare the plasma levels of cytokines with those
of SERO TL+ and endemic controls.
Plasma cytokine profiles in SERO TL+, HAT patients and
endemic controls
With the exception of IL5, significant differences were observed
between HAT patients, SERO TL+ and endemic controls for all
other cytokines measured in plasma (Figure 1). The lowest plasma
levels of all cytokines except for IL12 were observed in endemic
controls. IL1b, IL10, and INFc cytokine levels were significantly
higher in both HAT patients (p,0.0001, p,0.0001, p = 0.01,
respectively) and SERO TL+ individuals (p = 0.007, p = 0.004,
p = 0.03 respectively) than in endemic controls. IL2 (P,0.0001)
and IL4 (p,0.0001) were significantly higher in HAT patients
specifically, whereas IL8 (P,0.0001), IL6 (p= 0.001), and TNFa
(p = 0.005) were significantly higher in SERO TL+ individuals
only. SERO TL+ individuals were also characterized by very low
levels of IL12 (p,0.0001) as compared to controls and patients.
In order to get an overview of the cytokine response in SERO
TL+ and HAT patients and to explore similarities between
individuals or groups of individuals for all the cytokines in a single
analysis, we performed a Normed PCA including all 10 cytokines.
As shown in Figure 2A the two first components resume more
than 50% of the total variance of the data set. A representation of
the first factorial plan is given in Figure 2B. None of the recorded
covariates (HAT status, disease stage in HAT patients, age,
gender, or disease focus) appeared to be correlated with the
individuals coordinates on the x-axis. This part of the variance in
cytokine levels is likely explained by the occurrence of other
pathologies or diseases such as malaria, highly prevalent in the
area, but that were not recorded. Nevertheless the second
component, which accounted for 24.8% of variation (y-axis),
resulted in the separation of study subjects according to a HAT/
SERO TL+ gradient. The main cytokines contributing to the
variance of the second component were IL8, IL6, IL12, and
TNFa, indicating that SERO TL+ are mainly characterized by an
inflammatory response, which is not present in HAT patients
(Figure 2C).
Association of cytokine levels with the subsequent
evolution of infection in SERO TL+ subjects
In order to evaluate the prognostic value of the cytokine levels
determined at study inclusion on the subsequent evolution of the
parasitological and serological status in SERO TL+ individuals,
longitudinal follow-up were initiated. According to the results of
parasitological and serological tests performed during the follow-
up visits we could classify SERO TL+ into three distinct groups
(Figure 3). The first group (SERO TL+/HAT) comprised 12
individuals in whom the parasite was detected in body fluids
during follow-up. At study inclusion these individuals were
presumably in the early stage of the infection process but
trypanosomes were not detected at that time. The second group,
(SERO TL+/CATTneg) comprised 15 individuals in whom
trypanosomes were never detected but who displayed decreasing
CATT responses (with end titer becoming ,1/8). Similarly
decreasing CATT responses were also observed in treated HAT
patients in Guinea [19]; they were also observed in confirmed
HAT patients refusing treatment in Coˆte d’Ivoire and in whom
parasitological testing became subsequently negative [4], suggesting
Table 1. Phenotypic and demographic characteristics of the study sample.
Phenotypic groups Inclusion criteria’s N mean age [range] ratio male/female
Endemic controls CATT negative 40 39.4 [17–80] 1.5
trypanolysis test negative
no parasite detected in body fluids
HAT patients CATT$1/8 52 29.4 [4–70] 1.5
trypanolysis test positive
parasites detected in body fluids
SERO TL+ CATT$1/8 60 33.1 [5–70] 1.1
trypanolysis test positive
no parasite detected in body fluids
doi:10.1371/journal.ppat.1004469.t001
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that these SERO TL+ subjects were engaged in a process of self-
cure. The third group (SERO TL+/CATT$1/8) was composed of
13 individuals who maintained elevated CATT responses through-
out the follow-up period and who can be considered as asymptom-
atic carriers of parasite with parasitemia below the detection limit of
parasitological tests.
Univariate and multivariate analysis of cytokine levels in these
SERO TL+ showed that those individuals with the highest IL10
levels (p = 0.003, OR=13.09 [2.19–124.29]) and undetectable
TNFa (p = 0.009, OR=10.49 [1.72–101.12]) had a markedly
increased risk of developing HAT (Table 3, model I; Figure 4). In
contrast, the highest levels of IL8 (Table 3, model II; Figure 4)
were significantly associated with the group of SERO TL+ in
whom decreasing antibody responses were observed (p = 0.006,
OR=8.32 [1.79–53.44]). We did not observe any significant
association of cytokine levels with the maintenance of high CATT
responses (Table 3, model III).
Discussion
Whereas the concept of trypanotolerance has long been widely
accepted and studied in depth in cattle [20] and mice [21], leading
to major advances in our understanding of the genetic and
immunological mechanisms at play in T. congolense and T. b.
brucei infections [22,23], knowledge of how T. b. gambiense
interacts with its hosts lags far behind. One of the reasons is that
relevant animal models are not available. In most cases,
immunosuppressed animals are required to infect mice with T.
b. gambiense field isolates; alternatively, old laboratory-adapted
strains can be used but may not be very representative of ‘‘wild’’
parasites [24]. A second reason is that immunological studies in
human have focused on HAT patients and endemic uninfected
controls, thus exploring only part of the spectrum of immune
responses, i.e. the one at play in susceptible individuals. In the
present study we provide the first insights into the immune
Table 2. Cytokine levels measured in the CSF and plasma of HAT patients according to the disease stage.
CSF Plasma
Cytokines Stage median (pg/ml) [IQR]1 p-value2 median (pg/ml) [IQR] p-value
stage 1 29.8 [18.6–50.3] 0.0 [0.0–5.2]
IL8 early stage 2 49.9 [26.3–71.7] 0.0 [0.0–8.8]
late stage 2 81.5 [39.7–221.8] 0.0015 8.4 [0.0–14.3] 0.1290
stage 1 0.0 [0.0–5.4] 1.4 [0.0–3.5]
IL6 early stage 2 0.0 [0.0–4.6] 0.0 [0.0–4.8]
late stage 2 5.5 [0.8–12.4] 0.0126 2.7 [0.0–4.4] 0.7642
stage 1 0.0 [0.0–3.5] 7.6 [2.1–17.7]
IL10 early stage 2 3.9 [0.0–5.6] 7.9 [4.9–13.6]
late stage 2 15.3 [4.5–24.4] 0.0003 11.1 [7.1–25.7] 0.4368
stage 1 0.0 [0.0–0.0] 0.0 [0.0–0.0]
TNFa early stage 2 0.0 [0.0–4.0] 0.0 [0.0–5.2]
late stage 2 0.0 [0.0–6.8] 0.3142 0.0 [0.0–0.0] 0.1719
stage 1 0.0 [0.0–2.8] 1.2 [0.0–3.3]
IL12p70 early stage 2 2.1 [0.0–2.4] 3.0 [2.2–4.3]
late stage 2 0.0 [0–2.6] 0.7009 3.4 [0.0–5.8] 0.3039
stage 1 0.0 [0.0–0.0] 0.0 [0.0–12.8]
IL1b early stage 2 0.0 [0.0–0.0] 15.4 [0.0–28.5]
late stage 2 0.0 [0.0–0.0] 0.2276 16.5 [0.0–60.1] 0.1673
stage 1 0.0 [0.0–0.0]
IL5 early stage 2 0.0 [0.0–0.0]
late stage 2 0.0 [0.0–0.0] 0.6065
stage 1 5.7 [0.0–14.8]
IL2 early stage 2 6.4 [4.5–13.1]
late stage 2 6.5 [3.7–13.7] 0.5226
stage 1 4.9 [0.0–8.3]
IL4 early stage 2 3.2 [0.0–10.8]
late stage 2 5.1 [2.1–5.9] 0.8149
stage 1 0.0 [0.0–0.0]
INFc early stage 2 0.0 [0.0–7.5]
late stage 2 4.3 [0.0–10.4] 0.1367
1Interquartile range.
2P values are given for the three class comparisons (stage1, early stage 2, and late stage 2), p-values,0.05 are in bold.
doi:10.1371/journal.ppat.1004469.t002
Cytokines in Human Trypanotolerance
PLOS Pathogens | www.plospathogens.org 4 November 2014 | Volume 10 | Issue 11 | e1004469
response in human hosts (SERO TL+) who are apparently able to
control T. b. gambiense infection and we have evaluated the
prognostic value of cytokine levels on the subsequent evolution of
the serological and parasitological status in these subjects.
Cytokine profile and disease severity in HAT patients
Late-stage HAT develops when trypanosomes cross the blood-
brain barrier, inducing a neuroinflammatory process associated
with leukocyte infiltration into the central nervous system [25]. As
previously observed, elevated levels of cytokines with both
inflammatory (IL8 and IL6) and counterinflammatory (IL10)
properties were found in the CSF of late-stage patients
[12,13,26,27]. These results are in line with the proposal of using
these cytokines or other molecules intervening in the neuroin-
flammatory process [28–30] as late-stage diagnostic tools.
In this study we failed to show any significant association
between plasma cytokine levels and the different disease stages
although trends were observed for IL1b and INFc to be slightly
increased in late stage patients. However we had to rely on limited
numbers of subjects for this analysis and this may have precluded
finding evidence of small differences in cytokine levels according to
the disease stage. Noteworthy, weak association of plasma cytokine
levels with disease severity were also observed in other T. b.
gambiense endemic areas from central Africa [12,13] although in
these studies IL8 levels were slightly higher in early-stage patients.
This is in contrast to T. b. rhodesiense infections, in which plasma
concentrations of TNFa and INFc were clearly shown to be
correlated with disease severity [31,32]. This may be related to the
fact that T. b. rhodesiense infections are known to be acute,
progressing to late-stage disease in several months, which is in
clear contrast to the chronic nature of T. b. gambiense.
Nevertheless, important differences in plasma cytokine levels
were observed in HAT patients as compared to endemic,
uninfected controls, with highly significant differences (p,
0.0001) for IL1b, IL2, IL4, and IL10 and to a lesser extent for
INFc (p = 0.01). These results suggest that, in HAT patients, T-cell
responses are activated involving both Th1 and Th2 subsets.
Although the various animal model systems used have provided
conflicting evidence regarding the immunological factors that
influence the magnitude of resistance to African trypanosomes, the
overall picture in mice is that the host response requires the
contribution of both VSG-specific B- and T-cell responses and a
proper activation of the macrophage/monocyte phagocyte system
to control infection [33]. Type-1 cytokine responses (INFc,
TNFa), leading to macrophage activation to produce trypanotoxic
NO [34], are observed during the early stage of infection in both
susceptible and resistant mice. However, in resistant mice, the
cytokine profile switches to a type-2 response (IL4, IL10) during
the late/chronic stages of infection, presumably restricting
prolonged and exaggerated inflammatory responses [35]. One
Figure 1. Plasmatic cytokine profiles in HAT patients, SERO TL+ subjects, and endemic controls. Box plots of cytokine concentration are
presented. Boxes represent the medians and interquartile ranges and whiskers represent 10th and 90th percentiles. Asterisks indicate significant
differences over the control group: ****, p,0.0001; ***, p,0.001; **, p,0.01; *, p,0.05 (nonparametric Wilcoxon signed-rank test). Only cytokines
with significant differences are shown. Group effectives: control (n = 40); HAT (n = 52); SERO TL+ (n = 60).
doi:10.1371/journal.ppat.1004469.g001
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has to note that the term ‘‘resistant’’ in mouse models is often
exaggerated as these mice are characterized more by chronic
infection and delayed mortality, which seems to parallel the
infectious course in gambiense HAT. In contrast, early mortality
in highly susceptible mice is caused by an excessive activation of
the macrophage system, associated with an excessive production of
INFc and a systemic inflammatory syndrome [36], a picture that
appears more closely related to human T. b. rhodesiense infections.
Contrasted cytokine profiles are associated with the
diversity of infection outcomes
In SERO TL+ individuals the cytokine profile was clearly
different from that in HAT patients, although some features were
shared such as the induction of IL1b, IL10, and INFc, although to
lower levels than in HAT patients. As shown by the lower levels of
IL2 and IL4 and the almost absence of IL12, a cytokine that plays
a pivotal role in driving Th1-mediated cellular immunity, T-cell
Figure 2. Principal component analysis of cytokine responses in HAT patients and SERO TL+. A. Histogram of eigenvalues. The
eigenvalues, which corresponds to the amount of variance accounted by each component, are presented for the first ten components. The two first
components, which explain more than 50% of the total variance, are in black. B. First factorial plan (x-axis: first component, y-axis: second
component). The plan composed by the two first axis or dimensions is represented. It corresponds to an approximation of the cloud of points by a 2-
dimensional space. C. Absolute contribution of each cytokine to the variance of the second component.
doi:10.1371/journal.ppat.1004469.g002
Cytokines in Human Trypanotolerance
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responses appeared to be less activated in SERO TL+. In contrast,
SERO TL+ subjects were characterized by a marked inflamma-
tory response with elevated levels of IL8, IL6, and TNFa. In these
subjects, this inflammatory process appears to be Th1 independent
and thus more likely results from the innate activation of the
immune system, possibly through parasite-derived, macrophage-
activating molecules interacting with pattern recognition receptors
[37,38].
As previously reported in Guinea [7], follow-up of SERO TL+
individuals over a 2-years period showed that this group is
heterogeneous. Interestingly, SERO TL+ with the highest IL10
levels and none detectable TNFa at study inclusion had a
markedly increased risk of being confirmed by microscopy as HAT
patients during their follow-up (OR=13.09 [2.19–124.29] and
OR=10.49 [1.72–101.12] respectively). Increased IL10 and low
TNFa levels were also observed in HAT patients confirming their
association with disease susceptibility. Interestingly a line of
evidences indicates that the production of TNFa is involved in
the control of parasite growth but also in the development of
pathogenesis in experimental trypanosomiasis [39]. The mecha-
nisms by which TNFa interacts with trypanosomes (via direct
versus indirect actions) are still controversial and differ in the
various experimental models [40,41]. In the light of our results,
one can note that the production of TNFa was shown to be
induced by T. b. gambiense in human macrophages [42] and that
IL10 is well known for its macrophage deactivation properties.
Finally, an important finding of this study was that high levels of
IL8 (.30 pg/ml, OR=8.32, p = 0.006) were associated with the
group of SERO TL+ becoming negative in serology, suggesting
that this cytokine is a marker of the host immune response able to
eliminate infection. IL8 is a major cytokine involved in innate
immune responses. Its main function is to be a chemoattractant for
neutrophils, suggesting that these cells play an important role in
resistance to infection. In contrast to mice, neutrophils represent
50–70% of leukocytes in humans; they are essential effectors of
innate immunity notably through the production of antimicrobial
peptides [43], among which the cathelicidins were shown to be
typanotoxic [44].
Whereas the analysis of several cytokines only provides a limited
view of the host immune response to infection and precludes
drawing firm conclusion on the precise mechanisms controlling
parasite growth and or pathogenesis in human, for the first time
Figure 3. Evolution of the serological and parasitological status in SERO TL+ subjects. The progression of CATT end titers over time is
presented for individuals who were confirmed as HAT patients during their follow-up (A.), plain circles indicate that trypanosomes were detected by
microscopy in blood or cervical lymph nodes; individuals with decreasing CATT responses (B.) and individuals who maintained high serological
responses to the CATT during the follow-up period (C.).
doi:10.1371/journal.ppat.1004469.g003
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this study shows that contrasted cytokine profiles (summarized in
Figure 5) are associated with the diversity of infection outcomes
observed in T. b. gambiense endemic areas [1]. Unraveling the
mechanisms underlying human resistance/susceptibility to T. b.
gambiense and identifying the key controlling elements will require
further studies. Understanding how the human host is naturally
able to control and even cure infection is an exciting issue with the
potential of identifying novel therapeutic targets. Ongoing blood
mRNA profiling and whole genome association studies comparing
HAT patients and SERO TL+ individuals [45] will hopingly help
unraveling the mechanisms underlying human resistance/suscep-
tibility to T. b. gambiense.
New tools to improve the management of seropositive
subjects?
As part of the HAT elimination goal, increasing attention is
being paid to asymptomatic carriers. As available treatments are
expensive, still toxic, and require long-term hospitalization in
specific treatment centers, unconfirmed serological suspects are
usually not treated and sent back home by the mobile teams
screening the population. Regarding this situation, an important
finding of the present study is that markers of disease development
(high IL10, low TNFa) or self-cure processes (high IL8) exist in the
blood of SERO TL+. These cytokines, or other biomarkers yet to
be discovered, could thus be used to develop simple tests that help
make the appropriate therapeutic decision for this particular
category of subjects. Further studies based on larger samples from
different endemic areas will have to be performed to confirm the
prognostic value of these cytokines or other markers and define the
most appropriate concentration threshold to consider in order to
reach optimum specificity.
Conclusion
To our knowledge this study is the first to show that human
individuals able to resist T. b. gambiense are characterized by a
marked inflammatory cytokine profile, pointing out innate
immunity and possibly neutrophils as potential actors involved in
the control of infection. Future and ongoing studies using high
throughput methods to compare HAT patients and SERO TL+
will provide a more precise picture of the immune response
Figure 4. Box-plots of IL10, TNFa, and IL8 concentrations measured in the plasma of SERO TL+ subjects at study inclusion according
to follow-up results. SERO TL+/HAT: individuals confirmed as HAT patients (n = 12); SERO TL+/CATTneg individuals with decreasing CATT responses
with end titers becoming ,1/8 (n = 15); SERO TL+/CATT$1/8: individuals maintaining elevated CATT responses with end titers $1/8 (n = 13).
Significant differences in cytokine levels are indicated (**: 0.01,p,0.001; *: 0.05,p,0.01) for a group in comparison with the two others
(nonparametric Wilcoxon signed-rank test).
doi:10.1371/journal.ppat.1004469.g004
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occurring in these individuals and hopingly help identifying the
critical molecules or pathway controlling resistance/susceptibility
to T. b. gambiense HAT. We believe such studies will provide new
insights into the identification of novel therapeutic or prophylactic
targets and enable the design of new tools to improve the diagnosis
and management of parasitologicaly unconfirmed seropositive
individuals, an important challenge in the perspective of HAT
elimination.
Table 3. Prognostic value of cytokine levels in SERO TL+.
covariates with
univariate
p-value,0.11
covariates included
in the model threshold2 p-value OR3 CI4
Model I
SERO TL+/HAT IL-8 (0.056); IL-10 (0.017);
TNFa (0.048);
IL-10 .6 pg/ml 0.0034 13.09 2.19–124.29
G1 versus G2 and G3 IFNc (0.098); Age5 (0.06) TNFa ,threshold detection 0.009 10.49 1.72–101.12
Model II
SERO TL+/CATTneg IL-8 (0.009); IL-6 (0.095);
Age (0.066)
IL-8 .30 pg/ml 0.0056 8.32 1.79–53.44
G2 versus G1 and G3 Age - 0.048 - -
Model III
SERO TL+/CATT$1/8 none none - - - -
G3 versus G1 and G2
The prognostic value of cytokine levels measured at inclusion was evaluated by stepwise multivariate logistic regression analysis. For this, SERO TL+ individuals were
spited into three categories according to follow-up results: those who were confirmed as HAT patients (SERO TL+/HAT; n = 12; G1), those who presented decreasing
CATT responses (SERO TL+/CATTneg; n = 15; G2) and those who maintained high CATT responses and remained negative in parasitology (SERO TL+/CATT$1/8; n = 13;
G3). Three models were then constructed independently by a stepwise procedure comparing SERO TL+/HAT (model I), SERO TL+/CATTneg (model II) and SERO TL+/
CATT$1/8 (model III) to the two other groups.
1The covariate univariate p-value before the stepwise procedure is shown in between brackets.
2Cytokine levels were assigned to two class of equal size using the cytokine median value as the threshold.
3Odds ratio.
4Confidence interval.
doi:10.1371/journal.ppat.1004469.t003
Figure 5. Cytokine profiles and infection outcomes in gambiense HAT.
doi:10.1371/journal.ppat.1004469.g005
Cytokines in Human Trypanotolerance
PLOS Pathogens | www.plospathogens.org 9 November 2014 | Volume 10 | Issue 11 | e1004469
Supporting Information
Figure S1 Box-plots of cytokine concentrations mea-
sured in the plasma of HAT patients according to the
disease stage. Boxes represent the medians and interquartile
ranges and whiskers represent 10th and 90th percentiles. Group
effectives: stage 1 (n= 10); early stage 2 (n= 19); late stage (n = 23).
No significant differences between groups were detected (Kruskal-
Wallis nonparametric one-way analysis of variance).
(TIF)
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